CLINICAL TRIALS PROFILE FOR BRIMONIDINE TARTRATE AND TIMOLOL MALEATE

All Clinical Trials for Brimonidine Tartrate And Timolol Maleate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00435058 ↗	Visual Function Changes After Intraocular Pressure Reduction	Completed	University of Sao Paulo	N/A	2005-09-01	During the glaucomatous disease process, subpopulations of cells may be dead, damaged or healthy. Visual function changes could be observed due to a recovering of the suffering ganglion cells after the intraocular pressure reduction. This study aims at evaluating the correlation between intraocular pressure reduction and visual function changes in glaucoma patients after using antiglaucoma medications.
NCT00698945 ↗	Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)	Completed	Bp Consulting, Inc	Phase 4	2008-06-01	To assess the additional benefit of common adjunctive classes on the diurnal IOP curve in patients assessed as needing additional treatment to reach target intraocular pressure (IOP). To demonstrate superiority of IOP control with Istalol 0.5% QD compared to Brimonidine Tartrate 0.2% BID as adjunctive therapy in adults with uncontrolled IOP's (determined by P.I. based on target pressures) currently treated with Latanoprost 0.05% in the study eye(s).
NCT00811564 ↗	An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects	Completed	Allergan	Phase 4	2008-12-01	A three-month evaluation comparing the safety and efficacy of a fixed combination of 0.2% brimonidine tartrate/0.5% timolol maleate with that of latanoprost 0.005%, a prostaglandin analogue in glaucoma or ocular hypertension subjects
NCT00811850 ↗	Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow	Completed	Allergan	Phase 4	2008-12-01	A 10 week evaluation, crossover design study including a 3 week washout period between treatments, to determine the effects of Combigan® (fixed combination brimonidine tartrate 0.2%/timolol maleate 0.5%) and Cosopt® (fixed combination dorzolamide hydrochloride-timolol maleate ophthalmic solutions) on ocular blood flow as measured by retrobulbar blood flow.
NCT01284166 ↗	Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension	Withdrawn	Allergan	Phase 3	2013-07-01	This study will investigate the safety and efficacy of Triple Combination Therapy with dorzolamide hydrochloride/brimonidine tartrate/timolol ophthalmic solution in patients with glaucoma or ocular hypertension who have elevated IOP on dorzolamide hydrochloride/timolol maleate combination therapy.
NCT01987752 ↗	Safety and Efficacy of Combigan® Ophthalmic Solution in Korea	Completed	Allergan		2009-01-01	This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of Combigan® (brimonidine tartrate/timolol maleate) Ophthalmic Solution in patients with Open Angle Glaucoma or Ocular hypertension with insufficient response to local beta blockers treated as per standard of care in clinical practice.
NCT06761313 ↗	Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma	ACTIVE_NOT_RECRUITING	Federal University of So Paulo	PHASE4	2021-03-01	This project purpose is to evaluate the effectiveness, ocular surface quality, medication adherence and quality of life in 46 glaucoma patients in use of three separate drugs (Bimatoprost 0.3%, Timolol Maleate 0.5% and Brimonidine Tartrate 0.2%) comparing with triple combination, Triplenex. In this clinical trial approved by the Unifesp Etical and Research Comitte, volunteer glaucoma patients will be recruited from Unifesp Glaucoma Sector and VerMais Glaucoma Sector. They will be randomly divided em two groups,Group I is going to be treated with Triplenex (1 drop twice a day) and Grupo II with Brimonidine Tartarate (1 drop twice a day), Timolol Maleate (1 drop twice a day) and Bimatoprost (1 drop at night). At baseline visit a complete ophthalmolgical exam will be performed along with three questionnaires ("Ocular Surface Disease Index", "Glaucoma Treatment Compliance Assessment Tool" and "National Eye Institute Visual Function Questionnaire"),retinography, visual field, optic nerve OCT in all patients. This procedure will be repeated at baseline and within 4, 8, 12 weeks.

Clinical Trial Conditions for Brimonidine Tartrate And Timolol Maleate

Condition Name

Condition Name for Brimonidine Tartrate And Timolol Maleate
Intervention	Trials
Glaucoma	5
Ocular Hypertension	4
Quality of Life (QOL)	1
Glaucoma, Open-Angle	1

Condition MeSH

Condition MeSH for Brimonidine Tartrate And Timolol Maleate
Intervention	Trials
Glaucoma	6
Ocular Hypertension	4
Hypertension	3
Glaucoma, Open-Angle	2

Clinical Trial Locations for Brimonidine Tartrate And Timolol Maleate

Trials by Country

Trials by Country for Brimonidine Tartrate And Timolol Maleate
Location	Trials
United States	3
Brazil	1
Korea, Republic of	1

Trials by US State

Trials by US State for Brimonidine Tartrate And Timolol Maleate
Location	Trials
Indiana	1
New York	1
California	1

Clinical Trial Progress for Brimonidine Tartrate And Timolol Maleate

Clinical Trial Phase

Clinical Trial Phase for Brimonidine Tartrate And Timolol Maleate
Clinical Trial Phase	Trials
PHASE4	1
Phase 4	3
Phase 3	1

Clinical Trial Status

Clinical Trial Status for Brimonidine Tartrate And Timolol Maleate
Clinical Trial Phase	Trials
Completed	5
Withdrawn	1
ACTIVE_NOT_RECRUITING	1

Clinical Trial Sponsors for Brimonidine Tartrate And Timolol Maleate

Sponsor Name

Sponsor Name for Brimonidine Tartrate And Timolol Maleate
Sponsor	Trials
Allergan	4
University of Sao Paulo	1
Bp Consulting, Inc	1

Sponsor Type

Sponsor Type for Brimonidine Tartrate And Timolol Maleate
Sponsor	Trials
Industry	4
Other	3

Brimonidine Tartrate and Timolol Maleate: Clinical Trial Update, Market Analysis, and Projection

Last updated: April 28, 2026

What is the latest clinical and regulatory status for brimonidine tartrate and timolol maleate (BTM)?

BTM is an established fixed-dose combination for ocular hypotensive therapy in glaucoma and ocular hypertension. Current clinical development activity is largely incremental (labeling updates, formulation changes, and lifecycle management) rather than phase-advancing New Drug Applications. Most value in recent years comes from: (1) maintaining access and formulary positioning for branded generics, (2) defending patents around formulation, polymorphs/anhydrous forms (where applicable), and manufacturing processes, and (3) continuing long-term safety evidence consistent with standard ophthalmology outcomes (IOP lowering, ocular tolerability).

Clinical endpoints that continue to define evidence packages

• Primary efficacy: change from baseline in intraocular pressure (IOP) at defined time points (single-day and multi-week schedules).
• Safety: ocular adverse events (ocular burning/stinging, conjunctival hyperemia, dryness, irritation), systemic tolerability relevant to timolol (bradycardia, hypotension, respiratory effects).
• Comparative evidence format: head-to-head or add-on studies against timolol monotherapy or other combination regimens, and persistence of IOP control across dosing schedules.

Trial update (status framing)

• No late-stage, clearly differentiated Phase 3 “new mechanism” program is evident for BTM in the public clinical record; the asset’s lifecycle is dominated by established combination use and incremental clinical studies.
• Recent updates in practice are primarily driven by regulatory labeling and real-world adoption patterns rather than new clinical outcomes that would rebase the commercial narrative.

Which products drive the commercial position of BTM?

BTM’s commercial footprint is tied to branded and authorized generics that market the fixed-dose combination for ocular hypertension and open-angle glaucoma. The core commercial thesis is consistent: IOP reduction with a two-drug mechanism (alpha-2 agonist brimonidine + nonselective beta blocker timolol) delivered in a single ophthalmic formulation.

Therapeutic use

• Indication: lowering elevated IOP in patients with open-angle glaucoma or ocular hypertension (wording varies by jurisdiction and label).
• Dosing: typically twice daily for fixed-combination products (label-specific).

Positioning logic

• Timolol contributes beta-adrenergic blockade.
• Brimonidine contributes alpha-2 agonism with reduced aqueous humor production and increased uveoscleral outflow.
• Combination addresses IOP reduction magnitude and tolerability balancing versus monotherapy escalation.

What is the market opportunity for fixed-dose brimonidine tartrate and timolol maleate?

Market demand drivers

1. Chronic disease prevalence
   • Glaucoma is long-duration, and ocular hypertension is often managed long-term.
2. IOP control targets and adherence
   • Two-agent combinations can reduce the need for multiple bottles, improving adherence versus separate monotherapies.
3. Competitive substitution risk
   • Fixed-dose combinations compete with prostaglandin analogs, prostaglandin-combination products, and newer classes (where approved and reimbursed).
4. Safety and contraindication constraints
   • Timolol limits use in some patients with reactive airway disease or cardiac conduction issues; clinicians manage via selection and monitoring, which affects mix but does not eliminate demand.

Competitive landscape

BTM competes in the crowded glaucoma market with:

• Prostaglandin analogs (often first-line where tolerated and reimbursed)
• Prostaglandin fixed-dose combinations
• Other beta blocker combinations
• Alpha-agonist monotherapies and alternatives
• Newer mechanisms in certain geographies and formulary tiers

Practical implication: BTM’s commercial strength is typically strongest where payer formularies favor established lower-cost options, and where clinicians need reliable beta-blocker-based IOP lowering with add-on alpha-agonism.

How is the market projected to evolve for BTM through 2030?

Projection framework

Because BTM is an established molecule in fixed combination and commercialized in multiple jurisdictions through branded and generic channels, the projection is driven less by new clinical breakthroughs and more by:

• Volume stability/decline from substitution
• Price erosion from generic competition
• Share shifts to newer combination classes
• Reimbursement access cycles
• Persisting demand from chronic cohorts

Base-case projection (directional)

Overall market value trend: moderate erosion with stable to modestly declining unit volumes in many markets, offset by continued prescription volume in treatment-naïve and add-on segments where cost and clinician familiarity support use.

Unit volume trend: broadly stable to slight decline through 2030 in markets with high penetration of prostaglandin-based regimens and prostaglandin combinations.

Revenue trend: declines faster than volume due to pricing pressure from generic entry and therapeutic substitution to newer product classes.

What do key clinical outcomes imply for market performance?

BTM’s clinical value is anchored in measurable IOP reduction and predictable tolerability patterns aligned with timolol-brimonidine pharmacology. For commercial forecasting, this translates into:

• Sustained prescribing where patients need mid-strength IOP control and where adherence is improved via single-bottle combination.
• Ongoing label-driven use without dependence on “winner-takes-most” new mechanism adoption.
• Reclassification of BTM as add-on or later-line therapy in systems that prioritize prostaglandin analogs as first-line.

What patent and exclusivity themes matter for BTM (and why they affect projections)?

For mature fixed-dose ophthalmic combinations, market performance typically follows these cycles:

• Brand-to-generic transition timing drives major revenue step-down.
• Lifecycle patents around formulation, packaging, and manufacturing support longer tail revenue in certain territories, but usually do not prevent generic entry once core protection expires.
• Regulatory exclusivity in ophthalmology tends to be narrow compared with biologics; fixed-dose combinations are often constrained by competitive approvals.

Commercial takeaway: projection should be modeled on pricing erosion and volume substitution rather than on clinical breakthrough assumptions.

What are the key R&D and evidence priorities that would most impact BTM’s future?

Given the established role of BTM, future growth depends on incremental differentiation that can influence formulary or guideline positioning:

• Formulation refinements that improve ocular tolerability (reducing burning/stinging rates) and improve persistence.
• Pharmacokinetic and systemic safety characterization to support broad patient access.
• Real-world adherence and persistence evidence to justify combination value versus multiple bottles.
• Localized regulatory labeling expansions that open reimbursable patient subgroups.

Where does BTM fit in the treatment pathway and what does that mean for uptake?

Treatment pathway fit

• Typically used as an alternative or add-on when monotherapy does not achieve target IOP or is not tolerated.
• In many payer systems, BTM competes against first-line prostaglandin analogs and may shift toward later-line positioning over time.

Uptake implication

• Stable baseline demand from chronic cohorts
• Increasing share pressure in geographies with aggressive guideline adherence toward prostaglandins and their fixed combinations

Key takeaways

• BTM is a mature fixed-dose glaucoma combination with clinical evidence centered on IOP reduction and predictable tolerability.
• Recent clinical “updates” are mostly lifecycle-level rather than Phase 3 expansions that would reset the asset’s commercial narrative.
• Market performance is primarily driven by pricing erosion, generic substitution, and treatment-pathway shifts toward prostaglandin-based regimens.
• Through 2030, expect stable to modestly declining unit demand in many markets, with faster revenue erosion unless territory-specific pricing and reimbursement constraints support a longer revenue tail.

FAQs

1. Is brimonidine tartrate and timolol maleate still being studied in late-stage trials?
   Public development activity is largely incremental for this fixed combination, with no clear indication of a new late-stage mechanism-driven expansion in the open record.

2. What are the main clinical endpoints used to judge BTM performance?
   IOP lowering at prespecified timepoints and ocular/systemic safety tolerability.

3. What drives demand for BTM despite competition from other glaucoma drugs?
   Fixed-dose convenience that supports adherence and a reliable two-mechanism IOP lowering profile.

4. What is the biggest commercial risk for BTM through 2030?
   Therapeutic substitution to prostaglandin analogs and prostaglandin fixed combinations plus ongoing price pressure from generic competition.

5. What kind of future evidence would most support extended market access?
   Real-world adherence and persistence data, tolerability improvements, and labeling that expands reimbursable patient subgroups.

---

References

[1] FDA. Drug Approval Reports and product labeling for brimonidine tartrate and timolol maleate ophthalmic products. U.S. Food and Drug Administration.
[2] EMA. Public assessment and EPAR-related information for ophthalmic combination products containing brimonidine and timolol (when applicable). European Medicines Agency.
[3] ClinicalTrials.gov. Clinical trials listings for brimonidine tartrate and timolol maleate. U.S. National Library of Medicine.